Literature DB >> 24283833

HER2 and immunotherapy using monoclonal antibodies in colorectal cancer.

Ehsan Nazemalhosseini Mojarad1, Peter J K Kuppen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24283833     DOI: 10.2217/imt.13.131

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  5 in total

Review 1.  From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors.

Authors:  Federica Zoratto; L Rossi; E Giordani; M Strudel; A Papa; S Tomao
Journal:  Tumour Biol       Date:  2014-07-26

Review 2.  Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy.

Authors:  Seokhwan Chung; Richard A Revia; Miqin Zhang
Journal:  Nanoscale Horiz       Date:  2021-07-20       Impact factor: 11.684

3.  HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression.

Authors:  An Na Seo; Yoonjin Kwak; Duck-Woo Kim; Sung-Bum Kang; Gheeyoung Choe; Woo Ho Kim; Hye Seung Lee
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

4.  Human Epidermal Growth Factor Receptor Expression in Colorectal Cancer and Its Relationship with Clinicopathological Characteristics.

Authors:  Zhila Torabizadeh; Anahita Nosrati; Shadi Tahvildari
Journal:  Middle East J Dig Dis       Date:  2016-01

Review 5.  HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.

Authors:  Valentina Fanotto; Elena Ongaro; Karim Rihawi; Antonio Avallone; Nicola Silvestris; Lorenzo Fornaro; Enrico Vasile; Lorenzo Antonuzzo; Francesco Leone; Gerardo Rosati; Francesco Giuliani; Roberto Bordonaro; Mario Scartozzi; Giovanna De Maglio; Francesca V Negri; Gianpiero Fasola; Giuseppe Aprile
Journal:  Oncotarget       Date:  2016-10-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.